HTGF backs Amal Therapeutics’ CHF 3m series-A

The company will use the funds to progress the pre-clinical development of its vaccine for colorectal cancer and to further develop its Kisima technology platform for therapeutic tumor vaccination.

HTGF's last investment in a biotech startup was in January 2016, when it backed the seed round of diagnostics company SeNostic.

Previous funding
In February 2014, Boehringer Ingelheim Venture Fund and High-Tech Gründerfonds invested in a seed-funding round for Amal Therapeutics. The capital enabled the spinout from the University of Geneva.

Company
Amal Therapeutics is a Swiss biotech company that was incorporated in 2012 as a spin-off from the University of Geneva. The company develops Kisima, a novel proprietary vaccine technology platform dedicated to oncology indications.

People
Amal Therapeutics – Madiha Derouazi, (CEO).
High-Tech Gründerfonds – Frank Hensel (investment manager).
VI Partners – Diego Braguglia (general partner).
Boehringer Ingelheim Venture Fund – Frank Kalkbrenner (managing director).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• DACH
• Healthcare
• Venture
• Switzerland